Overall, most of the observed early longitudinal molecular signatures upon anti-TNF induction therapy were reproducibly associated with clinical outcome (endpoint: remission at week 14) in a second cohort of IBD patients, whereas the lack of replication of baseline difference points to a high heterogeneity of prior immune network states, at least in peripheral blood. This evidence concerns the gene TNF and inflammatory bowel disease.